Adjuvant dexamethasone

Small molecule

UUniversitas Padjadjaran

Adjuvant dexamethasone is one of 36 small molecule programs targeting Meningitis. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MeningitisActive, not recruiting

MeningitisPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

52 competitors in Meningitis

#DrugCompanyPhaseTrials

Cipro

Bayer

Approved

2 2

Doribax

Rifadin

Dalalone

CCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Approved

1 5

Cubicin

BBaxter Healthcare Corporation

Approved

—6

Intrathecal Methotrexate

Amgen

Approved

1 7

Sporanox

SSebela Pharmaceuticals Development LLC

Approved

—8

Intrathecal Cytarabine

Pacira Pharmaceuticals, Inc

Approved

1 9

Decadron

AAspen Global Incorporated

Phase 3

2 10

Zyvox

Pfizer

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Meningitis1 trial

High-dose Rifampicin for the Treatment of Tuberculous Meningitis: a Dose-finding Study

Completed·UUniversitas Padjadjaran·Phase 2/3·NCT02169882·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Adjuvant dexamethasone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Adjuvant dexamethasone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Adjuvant dexamethasone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Universitas Padjadjaran company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: UUniversitas Padjadjaran

Adjuvant dexamethasone

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Meningitis1 trial

References

Drug Info

Quick Facts

Related News